Cisplatin and Carboplatin in Testis and Ovarian Cancer: Pro Cisplatin

  • Stephen D. Williams


The availability of the analogs cisplatin and carboplatin has sparked considerable controversy as to the relative merits of the two agents. A number of randomized clinical trials have been done that address this issue. As expected, most of these trials have been done in the tumor types that are the most responsive to these agents, ovarian and testis cancer.


Ovarian Cancer Germ Cell Tumor Advanced Ovarian Cancer Southwest Oncology Group Combination Chemotherapy Regimen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adams, M., Kerby, I. J., et al. (1989). A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. Acta Oncol 28:57.CrossRefPubMedGoogle Scholar
  2. Alberts, D. S., Green, S., et al. (1992). Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10:706.PubMedGoogle Scholar
  3. Bajorin, D. F., Sarosdy, M.F., et al. (1993). Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 11: 598.PubMedGoogle Scholar
  4. Bokemeyer, Harstrick, C. A., et al. (1994). The use of carboplatin in malignant germ cell tumours. EurJ Cancer 30A: 721.CrossRefGoogle Scholar
  5. Childs, W. J., Nicholls. E. J., et al. (1992). The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis. Ann Oncol 3:29.Google Scholar
  6. Conti, P. F., Bruzzone, M., et al. (1991). Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III–IV ovarian carcinoma. J Clin Oncol 9:658.Google Scholar
  7. Edmonson, J. H., McCormack, G.M., et al. (1989). Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III–IV ovarian carcinoma: a comparison of equally myelosuppressive regimens. J Natl Cancer Inst 81:1500.CrossRefPubMedGoogle Scholar
  8. Advanced Ovarian Cancer Trialists Group. (1991). Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Brit Med J 303: 884.CrossRefGoogle Scholar
  9. Horwich, A. and Sleijfer, D. (1994). Carboplatin-based chemotherapy in good prognosis metastatic non-seminoma of the testis: an interim report of an MRC/EORTC randomised trial. Proc. Leeds Germ Cell Tumour Conference (abstract).Google Scholar
  10. Kattan, J., Mahjoubi, M., et al. (1993). High failure rate of carboplatin-etoposide combination in good risk non-seminomatous germ cell tumours. EurJ Cancer 29A: 1504.CrossRefGoogle Scholar
  11. Mangioni, C., Bolis, G., et al. (1989). Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst 81:1464.CrossRefPubMedGoogle Scholar
  12. McGuire, W. P., Hoskins, W. J., et al. (1993). A phase III trial comparing cisplatin/Cytoxan and cisplatin/Taxol in advanced ovarian cancer. Proc Amer Soc Clin Oncol 12: 255 (abstract).Google Scholar
  13. Swenerton, K., Jeffrey, J., et al. (1992). Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase IE study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 10:718.PubMedGoogle Scholar
  14. Taylor, A. E., Wiltshaw, E., et al. (1994). Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol 12: 2066–2070.PubMedGoogle Scholar
  15. ten Bokkel Huinink, W. W., van der Berg M. E. L., et al. (1988). Carboplatin in combination therapy for ovarian cancer. Cancer Treat Rev 15: 9.CrossRefPubMedGoogle Scholar
  16. Tjulandin, S. A., Garin, A. M., et al. (1993). Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumors. Ann Oncol 4: 663–667.PubMedGoogle Scholar
  17. Vermorken, J. B., ten Bokkel Huinink, W. W., et al. (1993). Carboplatin versus cisplatin. Ann Oncol 4: S41.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Stephen D. Williams
    • 1
  1. 1.Indiana University Cancer CenterIndianapolisUSA

Personalised recommendations